Biosynth Opens New Bioconjugation Suite in Berlin
Biosynth Unveils Expanded GMP Bioconjugation Facility in Berlin to Advance Next-Generation Therapeutics Biosynth, a global leader in providing essential raw materials and services for the life sciences and diagnostics industries,…
Medimaps Launches Next-Gen TBS Osteo Software in Europe
Medimaps Group Launches Next-Generation TBS Osteo Software Across Europe to Revolutionize Osteoporosis Detection Medimaps Group S.A., a Swiss-based global leader in AI-powered bone health solutions, has announced the European launch…
Novocure to Present Final PANOVA-3 Data in Pancreatic Cancer at ESMO GI 2025
Novocure to Present Final PANOVA-3 Data Highlighting Pain and Quality of Life Benefits of TTFields Therapy in Pancreatic Cancer at ESMO GI 2025 Novocure (NASDAQ: NVCR) announced that it will…
AC102 Eliminates Tinnitus in Preclinical Study
Experimental Drug AC102 Significantly Reverses Tinnitus and Repairs Auditory Damage in Preclinical Study A groundbreaking preclinical study has shown that a single dose of the novel compound AC102 can nearly…
Sunshine Biopharma Launches NIOPEG® into $10B Biologics Market
Sunshine Biopharma Launches NIOPEG® Biosimilar in Canada, Targeting $10B Biologics Market Sunshine Biopharma Inc. (NASDAQ: SBFM), a pharmaceutical company focused on developing and commercializing life-saving medicines across oncology, antiviral therapies,…
Pneumagen Publishes Positive Phase II Data for Broad-Spectrum Antiviral Neumifil
Pneumagen Publishes Promising Phase II Results of Neumifil in Peer-Reviewed Journal, Demonstrating Potential as Broad-Spectrum Antiviral for Respiratory Infections Pneumagen, a clinical-stage biotechnology company focused on developing broad-spectrum antivirals, announced…
Abeona Sells Priority Review Voucher for $155 Million
Abeona Therapeutics Secures $155 Million from Sale of Priority Review Voucher, Strengthening Financial Position Ahead of ZEVASKYN Launch Abeona Therapeutics Inc. (Nasdaq: ABEO), a clinical-stage biopharmaceutical company focused on developing…
BriaCell Adds New Phase 3 Trial Sites, Including Yale and LA Cancer Network
BriaCell Expands Phase 3 Breast Cancer Trial to Major U.S. Centers, Targets Enrollment Completion by 2026 BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ; TSX: BCT), a clinical-stage biotechnology company pioneering…
Alume Biosciences Publishes First-in-Human Bevonescein Nerve Imaging Data in Nature Communications
Alume Biosciences Publishes First-in-Human Data on Bevonescein for Nerve Imaging in Nature Communications Alume Biosciences, a late-clinical stage biotechnology company focused on improving surgical safety through nerve-illuminating technologies, has announced…
JCR Pharmaceuticals Completes Enrollment in JR-141 Phase III Trial
JCR Pharmaceuticals Completes Enrollment in Global Phase III Trial for JR-141 Targeting Hunter Syndrome JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR) has announced the successful completion of participant enrollment for…
OXLUMO® Now Reimbursed in Canada for PH1 Treatment
OXLUMO® (Lumasiran) Secures National Reimbursement in Canada for Treatment of Primary Hyperoxaluria Type 1 Alnylam Canada ULC has announced that OXLUMO® (lumasiran), a first-in-class RNA interference (RNAi) therapeutic, is now…
FDA Grants Accelerated Approval to Lynozyfic for Relapsed Multiple Myeloma
Regeneron’s Lynozyfic™ Secures FDA Accelerated Approval for Heavily Pretreated Multiple Myeloma Patients Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval…